Vantage logo

GSK’s tribulations continue

Two days ago GSK canned lete-cel. Now it is ditching otilimab, and daprodustat’s future is looking dicey.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.